Liminatus Pharma, Inc.
LIMN
$0.98
$0.077.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 276.79% | 473.14% | -- | 255.32% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 29.11% | 22.99% | -99.98% | -78.08% | |
| Operating Income | -29.11% | -22.99% | 99.98% | 78.08% | |
| Income Before Tax | -203.19% | 111.79% | 99.98% | 70.30% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -203.19% | 111.79% | 99.98% | 70.30% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -203.19% | 111.79% | 99.98% | 70.30% | |
| EBIT | -29.11% | -22.99% | 99.98% | 78.08% | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -96.22% | 108.93% | 100.00% | 71.01% | |
| Normalized Basic EPS | -156.74% | 0.58% | 100.00% | 69.77% | |
| EPS Diluted | -96.22% | 108.93% | 100.00% | 71.01% | |
| Normalized Diluted EPS | -156.74% | 0.58% | 100.00% | 69.77% | |
| Average Basic Shares Outstanding | 54.33% | 33.15% | 48.65% | -0.10% | |
| Average Diluted Shares Outstanding | 54.33% | 33.15% | 48.65% | -0.10% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |